Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Letrozole and an Investigational Agent Combination Found to be Beneficial for Advanced ER Positive Breast Cancer Patients | |
|
| |
 |  |  | Comments |  |
 |  |
 |
 |
 |  |
 |
 Text  |
Results of a phase II study presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium revealed that patients suffering from advanced estrogen receptor positive breast cancer can benefit from a treatment involving a combination of investigational agent PD 0332991 and letrozole.
"We are very encouraged by this improvement in progression-free survival," said Richard S. Finn, M.D., associate professor of medicine at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.
PD 0332991, which is being developed by Pfizer Inc., is a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4/6, which prevents cellular DNA synthesis by blocking cell cycle progression, Finn said. Previously published preclinical data have suggested that CDK 4/6 inhibition may play a role in the treatment of some breast cancers.
In the first part of this two-part, phase II study, Finn and colleagues randomly assigned 66 postmenopausal women with metastatic estrogen receptor (ER)-positive breast cancer to either the combination of PD 0332991 and letrozole or to letrozole alone. The second part of the study involved 99 patients with ER-positive cancers determined by screening to have certain genomic alterations, specifically cyclin D1 amplification and/or p16 loss, according to Finn.
Results showed that progression-free survival was 26.1 months for those in the combination arm versus 7.5 months for patients treated with letrozole alone. There was also a 45 percent response rate with the combination treatment versus 31 percent with letrozole alone in patients with measurable disease. The clinical benefit rate was 70 percent with the combination treatment and 44 percent with letrozole alone.
The combination of PD 0332991 and letrozole was also well tolerated. The most common adverse events were neutropenia, leukopenia, anemia and fatigue. "Importantly, this was uncomplicated neutropenia," Finn said. "There was no evidence of febrile neutropenia."
Further, after retrospectively analyzing the biomarkers for cyclin D1 amplification or p16 loss, the researchers found that "ER positivity was the only biomarker we really needed to select patients who were most likely to benefit from PD 0332991," he said.
"If these results are verified in a large, phase III study this could establish PD 0332991 as an important new treatment option for advanced ER-positive breast cancer in a frontline setting."
Source-Newswise
| |
|
|
More News on: Women and Cancer, Breast Biopsy, Pagets disease of the breast, Mastitis, Cancer and Homeopathy, Breast Cancer Facts, Cancer Facts, Cancer, Tattoos A Body Art, Breasts - Structures and Types
 Comment & Contribute
|
Related Links
Breast Cancer - Prevention and Management with Lifestyle Changes
Lifestyle choices may or may not cause breast cancer but healthy lifestyle changes can open up avenues beyond breast cancer. Good habits will allow ...
Breast Cancer Screening using Mammogram
Breast cancer if detected early can be completely cured. Mammography is used to screen women for breast cancer. ...
Male Breast Cancer
Most cases of male breast cancer are diagnosed between the ages of 60 and 70 years. Treatment of male breast cancer often involves ...
Recent Advances in the Management of Breast Cancer
The crab that invades the breast is no more a fear factor with all the advancements that medical science and customized protocols can fight breast ...
Clinical Trials Related News
Study Reveals Efficacy of Canakinumab in Tapering Use of Corticosteroids in SJIA Patients
The efficacy of canakinumab in tapering corticosteroid (CS) use in patients with SJIA was presented at EULAR 2013, the Annual Congress of the ...
Brodalumab can Lead to Significant Clinical Response in Psoriatic Arthritis Patients
Treatment with brodalumab can lead to significant clinical response and provide an acceptable safety profile in psoriatic arthritis patients, a new ...
Therapy That Destroys Bone Tumors Eases Pain
Patients with cancer that has spread to their bones are usually treated with radiation therapy to reduce pain. But if that treatment doesn't work, or ...
EORTC Investigates Imatinib Failure-free Survival in GIST Patients
In patients with localized, surgically resected, high/ intermediate-risk GIST, interim results of an EORTC intergroup trial have confirmed that ...
Value of Randomized Clinical Trials in Radiation Oncology Practice
Physicians, insurers and cancer patients want to be sure that whatever therapy is recommended and provided to patients is based on evidence, ...
Promising Trial Vaccine in China to Prevent Hand, Foot, Mouth Disease
A trial vaccine has provided significant protection against a virus that can cause potentially deadly hand, foot and mouth disease (HFMD) in ...
Medwonders Health Network
- Health News Index
|
|
 | Quiz on Cancer Looking for information on cancer? Go through medindia's Cancer quiz. 
|
- News Quick Links
 |
Breast
Complete Medindia Resources
|
| News Categories: |
| » | Research Reveals Early Age Screening Could Aid Breast Cancer Fight |
| » | Blood Tests can be Used to Detect Cancers Caused by Oral Sex |
| » | Exposure to BPA Boosts Risk of Prostate Cancer |
| » | Researchers Use Math to Kill Cancer Cells |
| » | Simple Ways to Prevent Skin Cancer |
| More Cancer News | |
|
Ask an Expert
